Knee osteoarthritis (OA) accounts for more than 80% of OA disease burden and has doubled in prevalence in the mid-20th century in the U.S. when compared with people who lived during early industrial era (1800s to early 1900s).1 Currently, the diagnostic and treatment armamentaria are limited. Disease progression is measured by joint space narrowing on…
Search results for: hip OA
A New Endowment Will Support Pediatric Rheumatology Fellowships
The Rheumatology Research Foundation has received a major donation from Audrey M. Nelson, MD, a retired rheumatologist from the Mayo Clinic in Rochester, Minn. The Audrey M. Nelson, MD, Pediatric Rheumatology Fellowship Endowment in Training will support training awards for pediatric rheumatology fellowships. This generous donation addresses the growing demand for pediatric rheumatologists to ensure…
ACR Policy: The Mouse That Roared
Do you remember the 1959 movie, The Mouse That Roared? Through a few small actions, the Duchy of Grand Fenwick, a small, often overlooked principality, becomes a superpower on the world map overnight. In many ways, rheumatology has been in the same position. We are a small specialty; we don’t have well-known diseases. Although our…
New Research Shows Knee Osteoarthritis Prevalence Is Rising
Studies highlighting the large numbers of people affected by knee osteoarthritis (OA) point to what clinicians who treat knee OA have been seeing for the past few decades: a substantial increase in the prevalence of knee OA in the U.S. and globally. Roughly 250 million people are affected by knee OA worldwide, and about 14…
Adalimumab May Help Maintain Remission in Non-Radiographic Axial Spondyloarthritis
NEW YORK (Reuters Health)—In patients with active non-radiographic axial spondyloarthritis (nr-axSpA) who achieved remission while taking adalimumab, researchers saw fewer flares among those who continued taking the drug than among those who stopped taking it. “The results showed that continued therapy with adalimumab was associated with a higher rate of maintenance of remission compared with…
The State of the Science: Annual Research Meetings Foster Collaboration & Mentorship
The 11th annual Investigators’ Meeting and the Rheumatology Research Workshop, held in June in San Francisco, were by all accounts great successes. California sunshine greeted more than 120 attendees as we came together to share the latest advances and updates in rheumatology research. These annual meetings have something for every research professional, whether you work…
Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis
New research shows tanezumab may be safe and effective for patients with osteoarthritis pain…
ACR Advocates for Access to Viscosupplementation for OA
In several U.S. states, Blue Cross/Blue Shield and other insurers have dropped or are considering dropping coverage of hyaluronic acid injection—or viscosupplementation—for patients with knee osteoarthritis. The decision appears to be based on guidelines published by the American Academy of Orthopaedic Surgeons in 2013, which at that time specified that research had not found hyaluronic…
Rheumatologists in U.S. on J-1 Visas Face Challenges After Fellowship
I am an alien rheumatologist. Are you? One in five rheumatology fellows is considered an alien. Under the Code of Federal Regulations Title 22 Chapter I Subchapter G Part 62 Subpart B Section 62.27, an alien physician is a foreign national who is a graduate of a school of medicine who comes to the U.S….
Case Report Illustrates Hypercoagulability in Behçet’s Disease
Behçet’s disease is a chronic, relapsing and remitting vasculitis with multisystem involvement. Commonly referred to as the Silk Road disease due to its prevalence in the Asian and Mediterranean region of the traditional Silk Road, Behçet’s was first described by Hippocrates as a triad of symptoms—genital and oral ulcers with uveitis—and attributed to links with…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 323
- Next Page »